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Abstract
Interstitial lung disease (ILD) is a major cause of morbidity and mortality in scleroderma (systemic sclerosis, or SSc).
Fibrocytes are a monocyte-derived cell population implicated in the pathogenesis of fibrosing disorders. Given the
recently recognized importance of caveolin-1 in regulating function and signaling in SSc monocytes, in the present
study we examined the role of caveolin-1 in the migration and/or trafficking and phenotype of monocytes and
fibrocytes in fibrotic lung disease in human patients and an animal model. These studies fill a gap in our
understanding of how monocytes and fibrocytes contribute to SSc-ILD pathology. We found that C-X-C chemokine
receptor type 4-positive (CXCR4
+)/collagen I-positive (ColI
+), CD34
+/ColI
+ and CD45
+/ColI
+ cells are present in SSc-
ILD lungs, but not in control lungs, with CXCR4
+ cells being most prevalent. Expression of CXCR4 and its ligand,
stromal cell-derived factor 1 (CXCL12), are also highly upregulated in SSc-ILD lung tissue. SSc monocytes, which
lack caveolin-1 and therefore overexpress CXCR4, exhibit almost sevenfold increased migration toward CXCL12
compared to control monocytes. Restoration of caveolin-1 function by administering the caveolin scaffolding
domain (CSD) peptide reverses this hypermigration. Similarly, transforming growth factor b-treated normal
monocytes lose caveolin-1, overexpress CXCR4 and exhibit 15-fold increased monocyte migration that is CSD
peptide-sensitive. SSc monocytes exhibit a different phenotype than normal monocytes, expressing high levels of
ColI, CD14 and CD34. Because ColI
+/CD14
+ cells are prevalent in SSc blood, we looked for such cells in lung tissue
and confirmed their presence in SSc-ILD lungs but not in normal lungs. Finally, in the bleomycin model of lung
fibrosis, we show that CSD peptide diminishes fibrocyte accumulation in the lungs. Our results suggest that low
caveolin-1 in SSc monocytes contributes to ILD via effects on cell migration and phenotype and that the
hyperaccumulation of fibrocytes in SSc-ILD may result from the altered phenotype and migratory activity of their
monocyte precursors.
Background
Scleroderma (systemic sclerosis, SSc) is a complex auto-
immune connective tissue disease involving inflamma-
tion and fibrosis of the skin, lungs and other internal
organs. The main cause of morbidity and mortality in
SSc is interstitial lung disease (ILD). Until recently, lung
fibrosis was generally believed to result from the prolif-
eration and activation of resident connective tissue
fibroblasts [1]. However, recent studies have also
indicated that fibroblasts can be derived from hemato-
poietic cells and by epithelial- or endothelial-mesenchy-
mal transformation. In fact, the notion that matrix-
producing cells could be derived from peripheral blood
mononuclear cells (PBMCs) peripheral blood cells is not
new. It was suggested by Metchnikov and others 100
years ago [2-5].
PBMCs play important roles in inflammation, fibrosis
and wound healing because of their immune functions
and because they are the progenitors of collagen-produ-
cing cells. The CD14
+ monocyte fraction contains pre-
cursors not only for macrophages but also for fibrocytes.
Circulating connective tissue cell progenitors (fibrocytes)
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PBMCs that express collagen together with hematopoie-
tic cell surface markers (for example C11b, CD34 and/
or CD45), but that do not express CD14. In addition, a
population of CD45
+/CD14
+/collagen I-positive (ColI
+)
cells described as “collagen-producing monocytes” was
recently observed at much higher levels in the periph-
eral blood of SSc patients than in control subjects [7].
Both monocytes and fibrocytes express on their surface
the C-X-C chemokine receptor type 4 (CXCR4). CXCR4
mediates the migration of these cells in response to stro-
mal cell-derived factor 1 (SD F - 1 ,o rC X C L 1 2 ) ,w h i c hi s
expressed at high levels in injured human and mouse
lung tissues [8]. In addition, fibrocytes contribute to tis-
sue remodeling by producing high levels of cytokines,
fibrogenic growth factors, extracellular matrix proteins
and matrix metalloproteinase [1,8-12].
Caveolin-1 plays a central role in several signaling cas-
cades in which it serves as a scaffolding protein that
binds to a variety of kinases and thereby regulates their
activity. As we have shown recently, caveolin-1 plays a
crucial role in regulating monocyte signaling and func-
tion in SSc. We found PBMCs from SSc-ILD patients to
be deficient in caveolin-1 and to overexpress CXCR4.
The phenotype of low caveolin-1 and high CXCR4
expression can be mimicked in normal monocytes by
transforming growth factor b (TGFb) treatment [13].
Our data, together with data from other groups, strongly
suggest that caveolin-1 is a key signaling molecule in the
monocyte-fibrocyte-fibroblast lineage and is responsible
for functional differences observed among cells isolated
from SSc-ILD and idiopathic pulmonary fibrosis (IPF)
patients compared to control subjects [14-16].
In the current study, we have extended our analysis of
the roles of caveolin-1 and CXCR4 in regulating the
functions of monocytes and fibrocytes and in the pathol-
ogy of SSc-ILD. We find that SSc monocytes differ func-
tionally and phenotypically from normal monocytes.
They are hypermigratory in response to CXCL12
because of their lack of caveolin-1 and their overexpres-
sion of CXCR4. Fibrocytes and “collagen-producing
monocytes” were detected in the blood and lungs of
SSc-ILD patients, but not in normal subjects. The ability
of the caveolin scaffolding domain (CSD) peptide to reg-
ulate CXCR4 expression and monocyte and fibrocyte
migration in vivo and thereby to inhibit the progression
of lung injury and/or fibrosis was demonstrated in bleo-
mycin-treated mice, suggesting that CSD peptide may
be a useful therapeutic agent in SSc-ILD.
Results
Fibrocytes in SSc-ILD lung tissue
Fibrocytes are cells expressing a hematopoietic marker
(CD45, CD34) and a mesenchymal marker (ColI). The
status of CD14 in these cells is controversial. In a recent
report, the term “fibrocyte” was reserved for CD14
-
cells, while CD14
+ cells were referred to as collagen-
producing monocytes [7]. CXCR4 is also present on
fibrocytes at high levels [12]. Fibrocytes and CXCR4
+/ColI
+ c e l l sa r ep r e s e n ti nt h el u n gt i s s u eo fI P F
patients, but not in lung tissue from normal subjects
[12]. Therefore, we looked for these cells in SSc-ILD
lung tissue. We identified these cells in the lung tissue
of all seven SSc-ILD patients examined (Figures 1A to
1C), but not in the lung tissue of healthy individuals.
Fibrocytes and CXCR4
+/ColI
+ cells were found both in
established lesions (for example, Figures 1B and 1C) and
at sites where active remodeling of alveoli was still
occurring (for example, Figure 1A). When we compared
the number of cells identified using different markers,
we found considerably more CXCR4
+/ColI
+ cells than
either CD34
+/ColI
+ or CD45
+/ColI
+ cells and slightly
more CD34
+/ColI
+ cells than CD45
+/ColI
+ cells (Figure
1D). The difference between CXCR4 and CD45 was sta-
tistically significant (P < 0.05), and the difference
between CXCR4 and CD34 approached statistical signif-
icance (P = 0.07). The relative lack of CD45
+ fibrocytes
is most likely due to the loss of CD45 that occurs once
fibrocytes enter the lung [1,17].
CXCR4 and CXCL12 are upregulated in the lungs of SSc-
ILD patients
Because the most common fibrocyte subset in SSc-ILD
lung tissue was positive for CXCR4, we compared the
expression of CXCR4 in SSc and normal lung tissues.
Western blot analysis showed a more than fourfold
increase in CXCR4 levels (P < 0.001) in SSc-ILD tissue
compared to normal lung tissue (Figures 1E and 1F).
We also compared the expres s i o no ft h eC X C R 4l i g a n d
CXCL12 in SSc and normal lung tissue. Little if any
staining was observed in control lung tissue sections
(Figure 2A). CXCL12 was strikingly upregulated in SSc-
ILD lung tissue (Figure 2B), both in cells with the mor-
phological characteristics of hyperplastic epithelial cells
lining the remaining airspaces and in alveolar macro-
phages (Figure 2C). No staining was detected in the
absence of primary antibody (Figure 2D).
Circulating fibrocyte subsets in SSc-ILD patients
Given the large number of fibrocytes in SSc lung tissue,
we wanted to determine the prevalence of these cells in
the peripheral blood of SSc patients. We found a greater
number of CD45
+/ColI
+ and CXCR4
+/ColI
+ cells in the
blood of SSc patients than in that of control subjects
(Figure 3). Interestingly, while CXCR4
+/ColI
+ cells were
more prevalent than CD45
+/ColI
+ fibrocytes in the lung
tissue of SSc patients, the reverse was true in the per-
ipheral blood. These results suggest that CXCR4
+/ColI
+
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SSc patients because they migrate rapidly and efficiently
into injured lung tissue.
SSc blood monocytes exhibit enhanced CXCL12-induced
chemotaxis in vitro
Since fibrocytes are derived from monocytes, SSc mono-
cytes overexpress CXCR4 and CXCR4 mediates the
migration of monocytes and fibrocytes into injured lung
tissue [8], we used micro-Boyden chambers (in which
cells placed in the upper chamber migrate through a
membrane toward the chemoattractant placed in the
lower chamber) to compare the migration of SSc and
Figure 1 Fibrocyte subsets in lung tissue of patients with
systemic sclerosis-interstitial lung disease. Fixed, paraffin-
embedded lung tissue sections from normal adults and adults with
systemic sclerosis-interstitial lung disease (SSc-ILD) were stained for
CD34, CD45, C-X-C chemokine receptor type 4 (CXCR4) and
collagen I (ColI). Nuclei were stained with 4’,6-diamidino-2-
phenylindole (DAPI) (blue). Left: low-magnification images. Right:
high-magnification images. The portion of the low-magnification
image that is presented at high magnification is boxed. (A) CXCR4
(red)/ColI (green). (B) CD45 (red)/ColI (green). (C) CD34 (red)/ColI
(green). (D) The number of double-labeled cells per field was
determined from images of sections obtained from seven SSc-ILD
patients and four normal subjects, with six randomly chosen fields
per sectio. *P < 0.05. CXCR4 expression was evaluated by
performing Western blot analysis on extracts of three normal lung
samples and four SSc-ILD lung samples (E) and then quantifying
them densitometrically (F) using actin as a loading control. Bars =
10 μm.
Figure 2 Stromal cell-derived factor 1 in human lung tissue.
Tissue sections of normal and SSc-ILD lungs were stained with anti-
stromal cell-derived factor 1 (anti-CXCL12) (red) and the nuclear
stain DAPI (blue). (A) Normal lung tissue section at × 10
magnification. (B) SSc-ILD lung tissue section at × 10 magnification.
(C) SSc-ILD lung tissue section at × 20 magnification. (D) SSc-ILD
lung tissue section at × 20 magnification without primary antibody
control. Note the massive CXCL12 staining in SSc-ILD lung tissue (B)
and (C) and little staining in normal lung tissue (A). e, epithelial
cells; M, macrophage. Bars = 10 μm.
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migration toward CXCL12 was enhanced almost seven-
fold in SSc monocytes compared to normal control
monocytes (Figure 4 and Table 1) (P < 0.0001).
To confirm and expand on these findings, we next
evaluated monocytes in which the effects of the under-
expression of caveolin-1 (for example, overexpression of
CXCR4) were reversed by treating cells with CSD pep-
tide. CSD peptide almost completely inhibited the
migration of both SSc and normal monocytes in
response to CXCL12 (Figure 4 and Table 1) (P <
0.0001). In addition, we also examined the migration of
normal monocytes in which the SSc phenotype (low
caveolin-1, high CXCR4) was induced by treatment with
TGFb.T G F b treatment enhanced the migration of nor-
mal monocytes 15-fold, and CSD peptide treatment
almost totally reversed the enhancement of migration by
TGFb (Figure 4 and Table 1) (P < 0.0001). In summary,
these data suggest that the recruitment of monocytes
and fibrocytes into the lung tissue of SSc patients is
mediated by the CXCR4/CXCL12 axis, which in turn is
regulated by TGFb and caveolin-1 [13,18].
SSc peripheral blood cell phenotypes
Given the altered migratory function of SSc monocytes,
we evaluated whether their phenotype might also be
altered. These studies revealed striking differences
between normal and SSc CD11b
+ cells. A higher percen-
tage of CD11b
+ SSc PBMCs CD11b
+ normal PBMCs was
CD14
+ (Figure 5A) (P < 0.05). When we characterized
these cells in terms of ColI and CD34 expression, we
found statistically significant differences (P < 0.05)
between scleroderma and normal PBMCs in CD11b
+/CD14
+/ColI
+-expressing, CD11b
+/CD14
+/CD34
+/ColI
+-expressing and CD11b
+/CD14
-/CD34
+/ColI
+-expressing
cells (Figure 5B). These observations indicate a major
increase in the percentage of both fibrocytes and collagen-
producing monocytes among SSc-ILD patients compared
to normal control subjects. The data are particularly strik-
ing for classic fibrocytes (CD11b
+/CD14
-/CD34
+/ColI
+
cells), in which eight of the nine subjects with the highest
levels of these cells were SSc-ILD patients. Our data are in
agreement with the recent observation that CD45
+/CD34
+/CD14
+/Col I
+ cells are present in the peripheral blood of
SSc patients [7]. We also evaluated the possibility that
Figure 3 Fibrocyte subsets in the peripheral blood of SSc-ILD
patients and normal subjects. Human peripheral blood
mononuclear cells (PBMCs) were isolated and analyzed by flow
cytometry for CD45, CXCR4 and ColI. Seven patients and seven
normal subjects were used in these studies. (A) Note that the
number of CD45
+/ColI
+ and CXCR
+/ColI
+ cells is higher in SSc-ILD
blood than in normal blood. Note that CD45
+/ColI
+ fibrocytes are
much more prevalent than CXCR4
+/ColI
+ cells. **P < 0.01. *P < 0.05.
(B) and (C) Primary data demonstrating that fluorescence levels
provided by isotype controls are readily distinguished from
fluorescence levels provided by specific antibodies. For FL1
fluorescence, primary antibodies are biotinylated isotype controls (B)
and biotinylated rabbit anti-ColI (C). For FL2 fluorescence, antibodies
are isotype control phycoerythrin (PE) (B) and anti-CD45 PE
monoclonal antibody (C).
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+ cells could be CD14
-/CD34
-. Indeed, there are
CD11b
+/ColI
+/CD14
-/CD34
- circulating cells, and the
levels of these cells are higher in SSc patients than in con-
trols, but the difference does not quite reach statistical sig-
nificance (data not shown).
CD14
+/ColI
+ cells are present in the lung tissue of SSc
patients but not of healthy individuals
To determine whether CD14
+/Col I
+ cells (see above)
exist in SSc patients in vivo, we examined lung tissue
for the presence of these cells. We identified CD14
+/ColI
+ cells in all seven of seven lung tissue samples
obtained from SSc-ILD patients, while no cells with this
p h e n o t y p ew e r ef o u n di nt h el u n gt i s s u es a m p l e sf r o m
healthy individuals (Figure 6). Specifically, 20.9 ± 5.8
CD14
+/ColI
+ cells were observed per × 20 microscopic
field (seven patients with six randomly chosen fields per
slide) compared to none of four normal lung tissue sam-
ples. These data further support our in vitro findings
and confirm the abnormality of the monocyte-fibrocyte-
fibroblast lineage in SSc.
CSD peptide treatment inhibits fibrocyte accumulation in
the lungs of bleomycin-treated mice
We have shown that CXCR4
+ fibrocytes accumulate in
the lung tissue of SSc patients (Figure 1) and that CSD
peptide treatment inhibits the overexpression of CXCR4
by SSc monocytes [13] and their enhanced migration
toward CXCL12 in vitro (Figure 4). To determine
whether the same mechanisms operate in vivo, we quan-
tified fibrocytes in the lung tissue of bleomycin-treated
mice and the effect of CSD peptide treatment. While
there is a population of cells that are slightly CXCR4
+
(CXCR4low) that are present at similar levels in both
Figure 4 Monocyte migration in vitro. The migration of normal and SSc-ILD monocytes toward CXCL12, the effect of TGFb on normal
monocyte migration and the ability of caveolin scaffolding domain (CSD) peptide to inhibit migration were quantified as described in Materials
and methods. Each symbol represents the results obtained with cells from a different donor. The median value obtained in each category is
indicated by a line. (A) Normal versus SSC-ILD ± CSD. Each symbol represents one subject. Note the almost sevenfold increase in migration in
SSc-ILD lung tissue and the almost complete inhibition of migration by CSD peptide. (B) Normal ± transforming growth factor b (TGFb) ± CSD.
Each symbol represents one subject. Note the 15-fold increase in migration induced by TGFb and the almost complete inhibition of migration
by CSD peptide.
Table 1 CSD peptide inhibits monocyte migration toward
CXCL12
a
Source TGFb CSD Peptide Cells/high-power field
(Mean ± SD)
Normal - - 12.0 ± 3.7
Normal -
+ 3.6 ± 1.1
Normal
+ - 187.7 ± 30.9
Normal
++ 15.9 ± 3.6
SSc - - 80.0 ± 8.6
SSc -
+ 16.7 ± 4.1
aCSD, caveolin scaffolding domain; CXCL12, stromal cell-derived factor 1;
TGFb, transforming growth factor b; SSc, systemic sclerosis. These data
summarize the results presented in Figure 4.
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fibrocytes to be the population of CD45
+/ColI
+/CXCR4high cells in the boxes that are present at
much higher levels in bleomycin-treated mice than in
saline-treated mice. Flow cytometric studies showed that
the percentage of CD45
+/CXCR4high/Col I
+ cells was
increased more than fivefold by bleomycin treatment
and that this increase was reduced by about 50% by
CSD peptide treatment (Figure 7). While few CD45
+/Col I
+ cells were observed in tissue sections from sal-
ine-treated mice, bleomycin induced a fivefold increase
in the number of CD45
+/Col I
+ cells (Figure 8). CSD
peptide treatment significantly inhibited this increase by
about 75%.
Discussion
Fibrocyte accumulation in lung tissue or peripheral
blood has been observed in a variety of fibrotic lung dis-
eases, including IPF [12,18-20], SSc [7,21], asthma [22]
and COPD [23]. In the current study, we have con-
firmed and expanded upon recent observations regard-
ing SSc-ILD fibrocytes [7]. Most important, we have
determined that the accumulation of fibrocytes in SSc-
ILD lung tissue may relate to the altered phenotype and
migratory activity of their monocyte precursors.
We observed fibrocytes in the lung tissue of SSc-ILD
patients, but not that of healthy individuals. We used
three different hematopoietic markers in these experi-
ments (in addition to the mesenchymal marker ColI)
and found the order of prevalence among fibrocyte sub-
sets to be CXCR4
+/ColI
+ >C D 3 4
+/ColI
+ >C D 4 5
+/ColI
+. Our data regarding fibrocyte accumulation and fibro-
cyte subsets in lung tissue are similar to observations
made regarding samples from IPF patients [12]. The
fibrocyte levels in peripheral blood are also similar in
IPF and SSc-ILD (about threefold enhancement in IPF
[24] and about twofold enhancement in SSc-ILD
patients), although a 15-fold enhancement was observed
Figure 5 Phenotype of SSc-ILD and normal monocytes. PBMCs were isolated and analyzed by using flow cytometry as indicated for their
expression of ColI, CD11b, CD14 and CD34. Each symbol represents the results obtained with cells from a different donor. The median value
obtained in each category for SSc-ILD patients and normal donors is indicated by a line. (A) Double-labeled analysis. Note that among CD11b
+
monocytes, CD14
+ cells are more prevalent among SSc-ILD cells than among normal cells. (B) Triple- and quadruple-labeled analyses. Note that
CD14
+/ColI
+, CD14
+/CD34
+/ColI
+, and CD14
-/CD34
+/ColI
+ cells are more prevalent among SSc-ILD CD11b
+ monocytes than among normal
CD11b
+ monocytes. *P < 0.05.
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tions in the lung, we detected fewer CXCR4
+/ColI
+ cells
than CD45
+/ColI
+ cells in the peripheral blood of SSc-
ILD patients. These observations are consistent with the
notion that the high level of CXCL12 we observed in
t h el u n gt i s s u eo fS S c - I L Dp a tients, combined with the
high level of CXCR4 we observed [13] in SSc-ILD
monocytes (that is, fibrocyte precursors), leads to a rela-
tively low steady-state number of CXCR4
+/ColI
+ cells in
the peripheral blood and their accumulation in the
lungs. A similar situation is also observed in bleomycin-
treated mice, in which there are very high levels of
fibrocytes in the lungs and low levels in the circulation
[8]. In summary, analyses of samples from IPF patients
[9,19], SSc-ILD patients [13] and mice treated with bleo-
mycin [8,18] (considered to be a model for both IPF and
SSc-ILD) demonstrate the central role of the CXCL12/
CXCR4 axis in the recruitment of fibrocytes into
damaged lung tissue.
We performed migration assays using CXCL12 as a
chemoattractant to directly examine the role of the
CXCL12/CXCR4 axis in regulating the migration of
monocytes in SSc-ILD. We previously showed that SSc-
ILD monocytes overexpress CXCR4 because of a defi-
ciency in the master signaling molecule caveolin-1 and
that this phenotype (that is, low caveolin-1 and high
CXCR4) can be generated in normal monocytes by
treatment with TGFb. In accord with their overexpres-
sion of CXCR4, we report herein that both SSc-ILD
monocytes and TGFb-treated normal monocytes
demonstrate extremely high degrees of migration in
response to CXCL12. In both cases, CSD peptide treat-
ment, which compensates for the lack of caveolin-1 and
thereby inhibits CXCR4 expression, almost completely
inhibited migration.
While we would like to have performed similar migra-
tion experiments using normal and SSc-ILD fibrocytes
produced by differentiation of monocytes in vitro,o u r
current observations identified differences between the
starting normal and SSc PBMC populations that made
these experiments too complex to perform and interpret
as part of the current study. These complexities are
related to ambiguities in the definition of fibrocytes.
Fibrocytes are defined as cells that express both hemato-
poietic markers and fibroblast markers. While all investi-
gators agree on CD45 and CXCR4 as hematopoietic cell
markers and ColI as a fibroblast marker, the use of CD14
and CD34 as hematopoietic cell markers is controversial.
The data dealing with CD14 are complex. It has been
proposed that CD14
+ monocytes (but not CD14
-
Figure 6 CD14
+/ColI
+ cells are present in SSc-ILD lung tissue. Fixed, paraffin-embedded adult lung tissue sections from normal and SSc-ILD
subjects were stained for CD14 and ColI. Nuclei were stained with DAPI (blue). Top: low-magnification images showing SSc-ILD adult lung tissue.
Bottom: high-magnification images showing SSc-ILD adult lung tissue. The portion of the low-magnification image presented at high magnification
is boxed. ColI, green; CD14, red. Note that CD14
+/ColI
+ cells are present in SSc-ILD lung tissue, but not in normal lung tissue. Bar = 10 μm.
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Page 7 of 13Figure 7 Flow cytometric quantification of CD45
+/CXCR4
+/ColI
+ fibrocytes in mouse lung tissue. Total lung cells were isolated from mice
(three to six mice in each category) ten days after saline or bleomycin treatment. The mice had been treated daily with CSD or control peptide
starting one day prior to saline or bleomycin treatment. CD45
+/CXCR4high/ColI
+ fibrocytes were quantified by performing flow cytometry. (A)
Results from a typical experiment in which lung cells from the indicated individual mice were gated based on CD45 staining, then resolved on
two-dimensional scatterplots based on their ColI and CXCR4 staining. Vertical and horizontal bars delimit the zone in which cells stained with
isotype controls are found. We refer to the cells that are slightly into the upper right quadrant as CXCR4low, and we refer to cells within the box
as CXCR4high. Therefore, the square box contains cells that are CD45
+/CXCR4high/ColI
+. (B) The percentage of cells falling within the square
box is presented for each category of mice. The data represent the average of from three to six mice in each category ± standard error of the
mean. **P < 0.01. *P < 0.05.
Tourkina et al. Fibrogenesis & Tissue Repair 2011, 4:15
http://www.fibrogenesis.com/content/4/1/15
Page 8 of 13monocytes) under the influence of factors secreted by T
cells and B cells differentiate into spindle-shaped, CD14
-
,C o l I
+ fibrocytes. Other investigators dispute the idea
that the precursors must be CD14
+ [18,25]. Results
from our laboratory and others [7,26] indicate that
CD45
+/ColI
+/CD14
+ cells exist and are particularly pre-
valent in samples from SSc-ILD patients. We find that
the subpopulations of SSc-ILD PBMCs that are CD11b
+/CD14
+ or CD11b
+/CD14
+/ColI
+ are much greater
than those found among normal PBMCs. The greater
fraction of CD14
+ cells raises the possibility that the
percentage of SSc-ILD monocytes able to differentiate
into fibrocytes is higher than the percentage for normal
monocytes. The greater fraction of CD14
+/ColI
+ cells
suggests that SSc-ILD monocyte preparations may con-
tain a significant number of collagen-producing mono-
cytes or cells that are partially differentiated into
fibrocytes. The physiological relevance of CD14
+/ColI
+
cells in the pathogenesis of SSc-ILD is further supported
by our observation that these cells are present in the
lung tissue of SSc-ILD patients, but not that of control
subjects.
In contrast to CD14, CD34 is not present on normal
monocytes [27]. Its presence on fibrocytes is controver-
sial, with some investigators reporting that it is present
[20] and others reporting that it is absent [28] on nor-
mal fibrocytes. Our observations regarding CD34 are (1)
that CD34
+/ColI
+ cells are prevalent in the lung tissue
Figure 8 CSD peptide inhibits the bleomycin-induced accumulation of CD45
+/ColI
+ fibrocytes in lung tissue. Sections from saline-treated
mice receiving the CSD peptide (CSD) or the control, scrambled peptide (Control) and sections from bleomycin-treated mice receiving the CSD
peptide (Bleo/CSD) or the scrambled peptide (Bleo) were harvested ten days after treatment, then stained for CD45 (green) and ColI (red). Nuclei
were labeled with DAPI (blue). (A) Upper row: merged low-magnification images. Lower row: merged high-magnification images. Bars = 10 μm.
(B) The average number of CD45
+/ColI
+ fibrocytes per field was determined in images from six mice in each category, with five fields per
mouse. **P < 0.01. *P < 0.05.
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agreement with other investigators [7,26], these CD34
+
peripheral blood cells from SSc-ILD patients can be
either CD14
+ or CD14
-. In summary, returning to cell
migration, to perform a complete analysis comparing
the migratory ability of normal and SSc fibrocytes, it
would be necessary to (1) separate CD14
+ and CD14
-
monocytes from each source, and (2) after the differen-
tiation of these populations in vitro into spindle-shaped
cells, separate these populations into CD14
+ and CD14
-
cells. In this manner, we could distinguish whether dif-
ferences in the ability of SSc-ILD and normal fibrocytes
and collagen-producing monocytes to migrate is due to
their source (for example, SSc-ILD versus normal) or to
their phenotype (for example, CD14
+ versus CD14
-).
We previously showed a variety of beneficial effects of
CSD peptide treatment on bleomycin-induced lung
fibrosis, including improved histopathology, inhibition of
alveolar epithelial apoptosis and inhibition of monocyte
accumulation in the lungs. Wea l s op r e v i o u s l ys h o w e d
that SSc-ILD monocytes overexpress the promigratory
cytokine receptor CXCR4 on the basis of their underex-
pression of caveolin-1 and that their overexpression of
CXCR4 is reversed by CSD peptide treatment. Given
that CXCR4 is the primary cytokine receptor on fibro-
cytes, that CXCR4 mediates the migration of fibrocytes
into the lung tissue of bleomycin-treated mice [8] and
that inhibiting the expression of the CXCR4 ligand
CXCL12 inhibits fibrocyte migration into the lung tissue
of bleomycin-treated mice [8], we used the bleomycin
model to examine the effects of CSD peptide on fibro-
cyte migration in vivo. In agreement with the results of
our in vitro studies, in vivo CSD peptide treatment
inhibited the accumulation of fibrocytes in the lung tis-
sue of these mice. The combined observations suggest
that CSD peptide treatment provides protection against
bleomycin-induced lung fibrosis in large part by inhibit-
ing the expression of CXCR4 by monocytes and fibro-
cytes and thereby inhibiting their migration into
damaged lung tissue.
Conclusion
Our data strongly support the idea that fibrocytes and
collagen-producing monocytes play a critical role in the
pathology of SSc-ILD and that these cells may differenti-
ate aberrantly and accumulate in the lungs because of
the altered phenotype and migratory properties of SSc-
ILD monocytes and monocyte-derived cells. Whether
fibrocytes and collagen-producing monocytes are dis-
tinct cell types or whether they are simply variations on
the fibrocyte theme (that is, cells expressing a hemato-
poietic marker and ColI) is an open question and possi-
bly just one of semantics. In other words, a fibrocyte by
any other name would “smell as sweet.” These studies
further highlight the potential ability of CSD peptide to
serve as a treatment for fibrotic lung diseases by inhibit-
ing the differentiation of fibrocytes and their migration
into damaged lung tissue.
Materials and methods
Patients
Under a protocol approved by the Institutional Review
Board for Human Research for a Rheumatology
Research Repository, patients with SSc-ILD were
recruited from the Scleroderma Clinic at the Medical
University of South Carolina (MUSC). All patients ful-
filled the American College of Rheumatology (formerly
the American Rheumatism Association (ARA)) criteria
for SSc [29]. Nine were classified as having diffuse cuta-
neous SSc, and four were classified as having SSc-over-
lap according to previously defined standards [13]. All
13 patients had evidence of SSc-ILD as previously
defined [13]. Demographic data are summarized in
Table 2.
Normal human lung tissue was obtained from the
Brain and Tissue Bank for Developmental Disorders
(Baltimore, MD, USA) or from the National Disease
Research Interchange (Philadelphia, PA, USA). Under a
protocol approved by the MUSC Institutional Review
Board for Human Research, SSc lung tissue was
obtained from autopsy specimens collected by the
MUSC Division of Pathology and Laboratory Medicine.
T i s s u ew a so b t a i n e df r o ms i xf e m a l eS S cp a t i e n t s( f i v e
white and one African-American) and one African-
American male SSc patient, all of whom had evidence of
SSc-ILD (Table 3).
Immunohistochemistry
Immunohistochemistry of human and mouse lung tis-
sue sections was performed as previously described
[14]. Briefly, paraffin-embedded sections were stained
with primary antibodies, appropriate Alexa Fluor 488-
or Alexa Fluor 555-conjugated secondary antibodies
(Invitrogen, Carlsbad, CA, USA) and the nuclear stain
4’, 6-diamidino-2-phenylindole (DAPI) (Invitrogen).
Images were collected using a Leica DMI 4000 B fluor-
escence microscope (Leica Microsystems, Inc., Buffalo
Grove, IL, USA). Primary antibodies were rat anti-
h u m a n( a n dm o u s e )C D 4 5a n dr a ta n t i - h u m a nC X C R 4
( B DP h a r m i n g e n ,S a nJ o s e ,C A ,U S A ,r a b b i ta n t i -
human (and mouse) CXCR4 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), rabbit anti-mouse ColI
(Cedarlane USA, Burlington, NC, USA), rat anti-
human (and mouse) CD14 (Biolegend, San Diego, CA,
USA), mouse anti-human CXCL12 (R&D Systems,
Minneapolis, MN, USA) and a rabbit antibody against
the human ColI type a1 C-terminal propeptide pre-
pared in our laboratory.
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Western blot analyses of human lung tissue were per-
formed as previously described [13,14].
PBMC isolation and monocyte enrichment
Human PBMC isolation and enrichment of monocytes
was performed as previously described [13]. Briefly, 40
mL of peripheral blood was drawn from SSc patients
and healthy individuals. Blood treated with anticoagulant
was diluted 1:2 with Hank’s Balanced Salt Solution and
centrifuged on a 1.083 g/mL Histopaque cushion
( S i g m a ,S tL o u i s ,M O ,U S A ) .P B M C sw e r eh a r v e s t e d
from the interface by centrifugation. Monocytes were
enriched from total PBMCs by immunodepletion using
a Dynal Monocyte Negative Isolation Kit (Invitrogen).
Peptide treatments
Treatment with CSD peptide and control peptides was
performed as previously described [14]. The CSD pep-
tide (amino acids 82 to 101 of caveolin-1; DGIW-
KASFTTFTVTKYWFYR) was synthesized as a fusion
peptide to the C terminus of the Antennapedia Interna-
lization Sequence (RQIKIWFQNRRMKWKK). Either
scrambled CSD attached to the Antennapedia Internali-
zation Sequence or the Antennapedia Internalization
Sequence alone was used as a control peptide. Neither
control peptide ever showed any effect.
Cell migration
Migration of normal and SSc monocytes was assessed as
described previously [30] with modifications. Briefly,
chemoattractant CXCL12 at 100 ng/mL in RPMI 1640
medium with 1% BSA (Sigma) was placed into the lower
wells of Neuro Probe Multiwell Chemotaxis Chambers
(Neuro Probe, Gaithersburg, MD, USA). A quantity of
25 μLo fc e l ls u s p e n s i o n( 1×1 0
6 monocytes/mL) with
Table 2 Clinical features of SSc patients
a
Patient characteristics Patients Controls
Caucasian males, n 39
Caucasian females, n 41 2
African-American males, n 12
African-American females, n 42
Asian females, n 11
Smokers, n 10
Former smokers, n 30
Mean age ± SD, years (range) 54.6 ± 9.8 (39 to 75) 43.7 ± 9.4 (22 to 57)
Disease: limited cutaneous, n 0 Not applicable
Diffuse cutaneous 9 Not applicable
Overlap 4 Not applicable
Disease duration, years: mean ± SD (range) 9.4 ± 6.6 (1 to 22) Not applicable
Pulmonary involvement (ILD) 13 of 13 (100%) Not applicable
Pulmonary Hypertension 5 of 13 (38.5%) Not applicable
GI involvement 12 of 13 (92.3%) Not applicable
Cardiac involvement 7 of 13 (53.8%) Not applicable
Renal involvement 0 of 13 (0%) Not applicable
Autoantibodies: ANA
+ 11 of 11 (100%) Not applicable
Scl-70
+ 4 of 11 (36%) Not applicable
Anticentromere 0 of 10 (0%) Not applicable
aSSc, systemic sclerosis; SD, standard deviation; ILD, interstitial lung disease; GI, gastrointestinal; ANA, antinuclear antibody.
Table 3 Clinical features of autopsy samples
a
Patient characteristics Patients Controls
Caucasian males, n 02
Caucasian females, n 52
African-American males, n 10
African-American females, n 10
Smokers, n 10
Former smokers, n 10
Mean age ± SD (range) 53.6 ± 11.4 (38 to
65)
51.3 ± 22.4 (23 to
77)
Disease: limited cutaneous, n 5 Not applicable
Diffuse cutaneous, n 2 Not applicable
Overlap, n 0 Not applicable
Pulmonary involvement (ILD),
n (%)
7 of 7 (100%) Not applicable
GI involvement, n (%) 5 of 7 (71.4%) Not applicable
Cardiac involvement, n (%) 5 of 7 (71.4%) Not applicable
Renal involvement, n (%) 1 of 7 (14.3%) Not applicable
aSD, standard deviation; ILD, interstitial lung disease; GI, gastrointestinal.
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RPMI 1640 medium with 1% BSA) was placed in the
upper wells. CSD or control peptide (5 μmol final con-
centration) was added to cells before they were placed
in the upper chamber. A 5-μm pore size polycarbonate
filter was used to separate the two compartments. After
incubation for 3 hours at 37°C in humidified air with
5% CO2, the filter was removed, fixed and stained with
DAPI (Invitrogen). The cells on the underside of the
membrane were photographed and counted in six high-
power fields per filter.
Flow cytometry
Human PBMCs were analyzed as described previously
[9,10] with modifications. Briefly, to label cell-surface
markers, cells (1 × 10
5 per aliquot) in PBS containing
01% BSA and 0.1% sodium azide (fluorescence-acti-
vated cell sorter (FACS) buffer) were incubated with
one or more of phycoerythrin (PE)-CD11b, CD14
PerCP, CD34 allophycocyanin (APC) (all from BD
Pharmingen), CD45 PE (BD Biosciences, San Jose, CA,
USA) and CXCR4 APC (R&D Systems), or with labeled
isotype control antibodies for 30 minutes at 4°C. Next,
cells were permeabilized using a cytofix/cytoperm kit
(BD Biosciences). ColI was labeled using biotinylated
anti-ColI (Rockland Immunochemicals Inc., Gilberts-
ville, PA, USA) and fluorescein isothiocyanate-conju-
gated streptavidin (BD Pharmingen). Biotinylated
isotype control antibody was also obtained from Rock-
land Immunochemicals Inc. After the cells were
washed in FACS buffer, fluorescence data were
acquired on a FACSCalibur flow cytometer and ana-
lyzed using BD CellQuest software (both from BD
Biosciences). At least 10,000 cells were analyzed per
condition.
Bleomycin experiments
Bleomycin-induced lung injury and CSD peptide treat-
ment were performed as previously described [13]. This
procedure was approved by the MUSC Institutional Ani-
mal Care and Use Committee. Ten days after bleomycin
treatment one group of mice was killed for immunohis-
tochemical analysis of lung tissue sections as described
above. Images were acquired using a Zeiss 510SML
Laser Confocal Microscope (Carl Zeiss, Thornwood,
NY, USA).
Ten days after treatment with bleomycin or saline
vehicle lungs were removed, diced and digested with
collagenase for flow cytometry of fibrocytes in lung tis-
sue [31]. Total lung cells were analyzed by flow cytome-
try as described above using antibodies against CD45
and CXCR4 prior to permeabilization and antibodies
against ColI after permeabilization.
Statistical analysis
Immunoreactive bands were quantified by densitometry
using ImageJ version 1.32 software (National Institutes
of Health, Bethesda, MD, USA). Raw densitometric data
were processed and analyzed using GraphPad Prism 3.0
software (GraphPad Software Inc., La Jolla, CA, USA).
Protein expression was evaluated by performing Wes-
tern blot analysis, immunohistochemistry or flow cyto-
metry, and data were assessed using Student’s t-test. In
all figures, statistical significance is expressed as ***P <
0.001, **P < 0.01 and *P < 0.05.
Abbreviations
BSA: bovine serum albumin; ColI: collagen I; CSD: caveolin-1 scaffolding
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